Ultime notizie per Odonate Inc (OTC:ODTCD) Azioni

Odonate Inc

TGT: -21% &#x7C; <a href="https://www.benzinga.com//node/42084138">Target shares are trading lower after the company reported worse than expected Q3 FY24 earnings and cut 2024 guidance.</a>
&nbsp;
QSI: 91% &#x7C; <a href="https://www.benzinga.com//node/42083527">Quantum-Si And Planet Innovation Will Partner On The Development And Manufacturing Of Quantum-Si's Novel Proteomics Platform, Proteus, Combined Teams Aim To Deliver Novel Proteomics Platform In Under Two Years</a>
&nbsp;
SVM: -16% &#x7C; <a href="https://www.benzinga.com//node/42075880">Silvercorp Metals shares are trading lower after the company announced a $130 million convertible senior notes offering.</a>

Movers

Trading Ideas

Market-Moving News for November 20th

Baird analyst Peter Benedict maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $90 to $100.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on Walmart, Raises Price Target to $100

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $249 to $225.

ICLR

Baird Maintains Neutral on Icon, Lowers Price Target to $225

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares are <a href="https://www.benzinga.com/premarket" target="_blank" rel="noreferrer noopener">trading lower in the premarket session on Wednesday</a>. 
The company reported third-quarter adjusted earnings per share of $1.85, <a href="https://www.benzinga.com/pressreleases/24/11/n42084061/target-corporation-reports-third-quarter-earnings" target="_blank" rel="noreferrer noopener">missing the street view of $2.30</a>. Quarterly total revenue of $25.67 billion (+1.1% year over year) missed the analyst consensus estimate of $25.90 billion.
&#8220;We encountered some unique challenges and cost pressures that impacted our bottom-line performance,&#8221; said&nbsp;Brian Cornell, chair and chief executive officer of Target.&nbsp;
The third-quarter gross margin rate decreased by 0.2 percentage points to 27.2%. This was primarily due to higher digital fulfillment and supply chain costs, driven by increased inventory levels, higher digital sales volume, and new supply chain facilities coming online. Operating income of $1.2 billion was 11.2% lower than last year.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42073589/target-q3-earnings-preview-analysts-expect-revenue-eps-growth-attention-may-quickly-turn-to-holiday-quarter" rel="noreferrer noopener">Target Q3 Earnings Preview: Analysts Expect Revenue, EPS Growth As Attention Turns To Holiday Quarter</a>
Target&#8217;s third-quarter comparable sales increased by 0.3%, driven by traffic and digital performance.
Guest traffic grew by 2.4% compared to the prior year. Digital comparable sales rose by 10.8%, reflecting nearly 20% growth in same-day delivery powered by Target Circle 360 and double-digit growth in Drive Up services.
Beauty comparable sales grew by more than 6%, while the Food &amp; Beverage and Essentials categories saw low-single-digit growth compared to the previous year.
Target exited the quarter with cash and equivalents worth $3.433 billion and inventory worth $15.165 billion. The company&#8217;s long-term debt and other borrowings as of quarter end was $14.346 billion.
Outlook Lowered: For FY24, the company now forecasts adjusted EPS between $8.30 and $8.90, down from the <a target="_blank" href="https://www.benzinga.com//node/40480867" rel="noreferrer noopener">previous guidance of $9.00 to $9.70</a>. The revised FY24 EPS outlook is also below the consensus estimate of $9.55.
Target expects its fourth-quarter adjusted EPS to range between $1.85 and $2.45, <a href="https://www.benzinga.com/calendars/guidance">below the consensus estimate of $2.66.</a>
Price Action: TGT shares are trading lower by 16.9% at $129.95 in the premarket session on Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41338328/taylor-swift-teams-up-with-target-for-exclusive-black-friday-merch-will-swifties-boost-q4-s" target="_blank" rel="noreferrer noopener">Taylor Swift Teams Up With Target For Exclusive Black Friday Merch: Will Swifties Boost Q4 Sales, Prove Donald Trump Wrong?</a></li>
</ul>

Earnings

Equities

Guidance

Markets

General

Target Q3 Earnings: Supply Chain Chaos Hits Bottomline, Slashes Annual Profit Outlook, Stock Tanks

NAMS

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $16 price target.

FBLG

D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target

D. Boral Capital analyst Jesse Sobelson maintains PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) with a Buy and lowers the price target from $2.25 to $1.5.

D. Boral Capital Maintains Buy on PEDEVCO, Lowers Price Target to $1.5

VERI

Veritone Announced The Launch Of Veritone Data Refinery A Groundbreaking Offering Designed To Help Enterprises Transform Vast Amounts Of Unstructured Data Into High-quality, AI -ready Assets

EPRX

Eupraxia Pharmaceuticals Unveiled New Pharmacokinetic Data From Its Phase 2A Eosinophilic Esophagitis Program

Rosenblatt analyst Blair Abernethy maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Buy and maintains $120 price target.

ESTC

Rosenblatt Maintains Buy on Elastic, Maintains $120 Price Target

This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA accelerated computing and Quantum-Si's advanced single-molecule protein sequencing and detection technologies, the collaboration aims to develop a robust data processing system. This system will keep pace with Quantum-Si's rapidly evolving technology advancements, generating single-molecule protein insights to deepen our understanding of the proteome and develop innovative solutions through research, drug discovery, and healthcare AI.

Large Cap

Health Care

Contracts

Tech

NVDA

Quantum-Si Announced A Collaboration With Nvidia To Develop Its New Proteomics Platform, Proteus, And Advance Quantum-Si's Core Technologies Of Amino Acid Binders And Aminopeptidases Using Nvidia AI And Accelerated Computing

NTRS

Northern Trust Launched An Enhanced Active Collateral Solution Designed To Help Institutional Investors Manage Their Collateral More Efficiently While Meeting The Demands Of Continual Market Change

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and raises the price target from $98 to $100.

Rosenblatt Maintains Buy on Dolby Laboratories, Raises Price Target to $100

WLFC

Willis Lease Finance Announces Its Subsidiary Entered Into A Master Services Agreement With McDermott For Early Engineering, Procurement And Construction  Related Services For Its SAF Initiative

Dycom Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) shares are trading higher after the company reported its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42083467/dycom-industries-inc-announces-fiscal-2025-third-quarter-results" rel="noreferrer noopener">third-quarter FY25 results</a>.
Contract revenue increased&nbsp;12.0%&nbsp;Y/Y to&nbsp;$1.272&nbsp;billion, beating the consensus of&nbsp;$1.231 billion.
Adjusted EBITDA increased to&nbsp;$170.7&nbsp;million from&nbsp;$143.2&nbsp;million a year ago. Adjusted EPS&nbsp;of&nbsp;$2.68 surpassed&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the street view of&nbsp;$2.35</a>.
As of October&nbsp;26, cash and equivalents stood at&nbsp;$15.3 million. During the nine&nbsp;months ended October&nbsp;26,&nbsp;the company bought back 210,000 shares of common shares in open market&nbsp;transactions for $29.8 million.
Outlook: For the&nbsp;fourth quarter, Dycom anticipates a mid- to high single-digit percentage increase in total contract revenues, which included the company expectation&nbsp;of around&nbsp;$35 million of acquired <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">contract revenues for the quarter</a>.
Adjusted EBITDA margin is projected to increase by about 25 basis points Y/Y.
Investors can gain exposure to the stock via&nbsp;First Trust RBA American Industrial Renaissance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRR#NASDAQ">AIRR</a>) and&nbsp;Hilton Small-MidCap Opportunity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCO#NASDAQ">SMCO</a>).
Price Action: DY shares are up 3.06% at $209 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42083607" target="_blank" rel="noreferrer noopener">As Spirit Airlines Files For Bankruptcy Experts Weigh Potential Impact On Flight Prices: &#8216;This Is Not A Black And White Situation&#8217;</a></li>
</ul>

Mid Cap

AIRR

SMCO

Dycom Industries Posts Strong Q3 Results: EPS Beats Estimates By 14%

Rosenblatt analyst Catharine Trebnick maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Buy and raises the price target from $90 to $100.

FTNT

Rosenblatt Maintains Buy on Fortinet, Raises Price Target to $100

ACXP

Acurx Pharmaceuticals Announced Today That The Company's Board Of Directors Approved The Purchase Of Up To $1 Million In Bitcoin To Hold As A Treasury Reserve Asset

Biotech

GDTC

CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological Malignancies

LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) reported quarterly sales of $13.10 million which missed the analyst consensus estimate of $28.05 million by 53.30 percent. This is a 58.02 percent decrease over sales of $31.21 million the same period last year.

Earnings Misses

LUXH

LuxUrban Hotels Q3 Sales $13.10M Miss $28.05M Estimate

TANDEM will support global regulatory filings for the 10 mg obicetrapib and 10 mg ezetimibe fixed-dose combination in adult patients with heterozygous familial hypercholesterolemia ("HeFH") and/or atherosclerotic cardiovascular disease ("ASCVD") or multiple ASCVD risk factors, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

NewAmsterdam Pharma Announced Topline Data From Its Phase 3 TANDEM Trial, Meeting All Co-Primary Endpoints, Including The Obicetrapib-Ezetimibe Fixed Dose Combination Achieving An LS Mean Reduction Of 48.6% Compared To Placebo At Day 84

Comments

Odonate Inc

Notizie

Ultime notizie per Odonate Inc (OTC:ODTCD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO